ARTICLE | Emerging Company Profile
Atalanta’s next-gen RNAi branches deeper into brain, hooks Biogen and Genentech
Emerging Company Profile: Newco launches with UMass Med’s branched siRNA tech, $110M in cash
January 12, 2021 2:05 AM UTC
A rush of interest following the publication of Atalanta’s brain-optimized siRNA tech enabled the UMass Medical School spinout to launch with two high-profile partners in hand.
Atalanta Therapeutics Inc. emerged from stealth Monday with $110 million in total funding, comprising a series A investment from F-Prime Capital and upfront payments from two partners: Biogen Inc. (NASDAQ:BIIB) and the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY). The sizes of the three components are undisclosed...